Lee Ann Baxter-Lowe, PhD, (D)ABHI

Lee Ann Baxter-Lowe, PhD, dABHI

Director, HLA Laboratory
Professor of Clinical Pathology, Keck School of Medicine of USC

Dr. Lee Ann Baxter-Lowe is the Director of the HLA Laboratory at Children's Hospital Los Angeles and also serves as an Adjunct Clinical Professor at the University of Southern California. Her research interests include the role of HLA polymorphism in health and disease, the impact of HLA mismatching in allogeneic transplantation, characterization of chimerism after transplantation, and development of improved methods for HLA typing. She is an author for more than 150 scientific publications and 200 abstracts. She recently served as the Program Chair for an ASHI-sponsored meeting on Next Generation sequencing and presented a NGS Workshop at ASHI’s 2016 annual meeting. She holds 5 patents related to HLA typing. She has had a long-standing commitment to policy development and has recently completed terms as the chair of the Histocompatibility Committee of the United Network for Organ Sharing (UNOS) and histocompatibility representative to the UNOS Kidney Committee. She is on the Editorial Board of Human Immunology and is the Associate Editor for The ASHI Quarterly.


Graduate School

University of Wisconsin-Madison (PhD)



American Board of Histocompatibility and Immunogenetics: Diplomate
State of California: Histocompatibility Laboratory Director
State of New York: Laboratory Director for Histocompatibility and Engraftment Monitoring

Professional Memberships

American Association for the Advancement of Science
American Society for Histocompatibility and Immunogenetics
American Society of Hematology
American Society for Blood and Marrow Transplantation


National Science Foundation Undergraduate Research Grant (1971)
Peterson Fellowship (1974)
Babcock Fellowship (1975)
National Institutes of Health Post-doctoral Fellowship (1977-80)
American Society for Histocompatibility and Immunogenetics Scholar (1990)
Young Investigator Award, American Society for Histocompatibility and Immunogenetics (1991)


Pidala J, Wang T, Haagenson M, Spellman SR, Askar M, Battiwalla M, Baxter-Lowe LA, Bitan M, Fernandez-Viña M, Gandhi M, Jakubowski AA, Maiers M, Marino SR, Marsh SG, Oudshoorn M, Palmer J, Prasad VK, Reddy V, Ringden O, Saber W, Santarone S, Schultz KR, Setterholm M, Trachtenberg E, Turner EV, Woolfrey AE, Lee SJ, Anasetti C. (2013) Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood 122:3651-8.

Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, Arcese W, Barker JN, Baxter-Lowe LA, Brown M, Fernandez-Vina MA, Freeman J, He W, Paolo Iori A, Horowitz MM, Locatelli F, Marino S, Maiers M, Michel G, Sanz GF, Gluckman E, Rocha V (2014) Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood 123:133-40.

McGuinn C, Geyer M, Zhezhen J, Garvin J, Satwani P, Bradley B, Bhatia M, George D, Duffy D, Morris E, van de Ven C, Schwartz J, Baxter–Lowe LA, Cairo M (2014) Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia. Pediatric Blood & Cancer 61:1289–1294.

Bhatia M, Jin Z, Baker C, Geyer MB, Radhakrishnan K, Morris E, Satwani P, George D, Garvin J, Del Toro G, Zuckerman W, Lee MT, Licursi M, Hawks R, Smilow E, Baxter-Lowe LA, Schwartz J, Cairo MS. (2014) Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant. 2014 May 5. [Epub ahead of print].

Fernandez-Vina MA, Wang T, Lee SJ, Haagenson M, Aljurf M, Askar M, Battiwalla M, Baxter-Lowe LA, Gajewski J, Jakubowski A, Marino S, Oudshoorn M, Marsh SGE, Petersdorf EW, Schultz K, Turner V, Waller E, Woolfrey A, Umejiego J, Spellman SR, Setterholm M (2014) Identification of a Permissible HLA Mismatch in Hematopoietic Stem Cell Transplantation Blood 123:1270-8.


Allogeneic Transplantation, Chimerism/Microchimerism, Histocompatibility, HLA Antibodies, HLA Polymorphism